News

pharmaphorum4d
Mesoblast finally pushes GvHD cell therapy over finish line
He was a little coy on pricing, saying that it would be in line with other cell-based therapies that deliver long-term clinical benefits. The company is also developing MSC therapies for other ...
ascopubs.org1d
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor ...
Validation of lymphocyte to monocyte ratio in resected small bowel adenocarcinoma as a predictor of survival. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This abstract does ...
Nature6d
Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype
Figure 1: Expression of pRb and p16 as a function of cell density. Figure 3: hTERT clones undergo normal growth arrest in response to PALA and γ-irradiation. Figure 4: hTERT clones arrest ...